S-(-)-Carbidopa, >=98% (TLC), powder

Code: c1335-100mg D2-231

Not available outside of the UK & Ireland.

Biochem/physiol Actions

Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby i...


read more

Your Price
£286.00 100MG
REQUEST

Not available outside of the UK & Ireland.

Biochem/physiol Actions

Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby increasing CNS concentrations of effective compounds. Selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells by increasing H2O2 in these cell lines, which are sensitive to reactive oxygen species.

General description

Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.

Packaging

100 mg in glass bottle

25 mg in poly bottle

assay≥98% (TLC)
formpowder
Gene Informationhuman ... DDC(1644)
InChI keyTZFNLOMSOLWIDK-JTQLQIEISA-N
InChI1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
Quality Level200
SMILES stringCC(Cc1ccc(O)c(O)c1)(NN)C(O)=O
solubilitymethanol and 1 drop HCl: 4.90-5.10 mg/mL, clear, colorless to faintly yellow
storage temp.−20°C
Code
Description
Unit Size
List Price
Qty
C1335-25MG
S-(-)-Carbidopa, >=98% (TLC), powder

Unit:25MG
List Price: £95.40
Source:List Price
ADD
Cas Number28860-95-9
This product has met the following criteria: